London Daily

Focus on the big picture.
Wednesday, Jul 30, 2025

What do we know about the Russian vaccine

What do we know about the Russian vaccine

Study findings on the Russian vaccine against Covid-19 show that it is safe, well tolerated and induces cellular immune responses in 100% of healthy participants.

This was published by The Lancet magazine, based on a preliminary study carried out by researchers from the Russian government. This study was evaluated by a rereading committee of the British medical journal prior to its publication.

All reported adverse events on the Russian vaccine were mostly mild. However, a comparative clinical study with other vaccines is needed to confirm these findings, the publication notes.


The information is released after the Russian authorities announced, last August, their vaccine against Covid-19, which they call Sputnik V, in honor of the first satellite launched into space, in 1957.

On August 11, it was reported that Sputnik V was entering the third and final phase of clinical trials.

What elements emerge from the article published in The Lancet? Sputnik V consists of two components: recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5); and that both rAd26 and rAd5 contain the SARS-CoV-2 virus protein S gene.

It should be explained that adenoviruses are a group of viruses that typically cause respiratory diseases, such as colds, conjunctivitis (eye infection), bronchiolitis, pneumonia, among others. Both components were developed, manufactured and stored by the National Research Center for Epidemiology and Microbiology NF Gamaleya (Moscow).

During vaccination, component 1 is introduced for the first time and, after three weeks, component 2. According to the evaluation of the developer, the immunity can last up to two years. Then you may need to vaccinate again. However, this remains to be explored in post-marketing studies, explained Vadim Tarasov, director of the Institute of Transmission Medicine and Biotechnology and head of the department of pharmacology at Ivan Sechenov University.

How were the studies done?

It was precisely at the Ivan Sechenov University that preclinical trials of two dosage forms of the Russian vaccine were carried out. The other place where the studies took place was at Burdenko Hospital.

Healthy adult volunteers (men and women), whose ages ranged from 18 to 60 years old, were enrolled for the Russian vaccine studies. Between June 18 and August 3, 2020, they enrolled 76 participants in the two studies Thus, in each study, 38 volunteers were vaccinated. More men than women participated in the study.

According to Tarasov, the study itself was carried out in two stages. One of them was the observation of volunteers for 14 days in isolation to prevent them from contracting the coronavirus infection. Once the observation was completed and it was confirmed that the volunteers did not have Covid-19, they were transported, with all possible precautions, to the cardioangiology center of the Ivan Sechenov University.

In this hospital, 38 volunteers stayed 28 days after the first injection of the drug and were discharged one week after the second. Their stay in the hospital was organized to protect them from the possibility of becoming infected and thus dropping out of the study or entering incorrect data on the immunity developed, he explained.

It was extremely important work, to reliably assess the response of the immune system and draw preliminary conclusions about the effectiveness of the drug, says Sechenov.

According to the study published in The Lancet, the most common reactions among participants were pain at the injection site, hyperthermia (body temperature 37–38 ° C), headache, fatigue, and muscle and joint pain. No serious adverse events were reported during the investigation.

Notably, the volunteers had no infectious diseases at the time of vaccination and for 14 days prior to vaccination, and did not receive any other vaccines within 30 days of participating in the study.

Caution

When the world announcement of Sputnik V was made, it was greeted with skepticism by many researchers by the scientific community. Its efficacy and safety were questioned, mainly due to the absence of public data on the trials conducted up to that point.

This opinion is largely due to misunderstanding that the preparation in question is registered in the Russian Federation 'conditionally', says Sechenov. As he explains, this is a well-known and widely used mechanism in the United States, the European Union, Japan and other countries with a developed regulatory system. Its essence lies in the fact that if it is necessary to put the drug into practice as soon as possible, for example, for orphan or oncological diseases, during epidemics, etc., and it is impossible to conduct full clinical trials, the drug is temporarily registered with indications of limited use, which are based on the results of clinical trials already carried out, he details.

At the same time, a mandatory requirement is to conduct post-registration studies with the participation of a certain number of patients at a given time, and any use of the drug becomes part of the study.

This is the case of the Sputnik V vaccine, whose registration certificate was issued until January 2021, and as a prerequisite, clinical trials with 40,000 participants were established, says Sechenov.

As has been announced, this will be the objective of the phase 3 trial (which will include 40,000 participants), of various ages and with different risk levels.

Since the announcement made by President Vladimir Putin last August, the World Health Organization (WHO) has urged Russia to follow the established protocol and comply with all the phases necessary to develop a safe vaccine.

The WHO will not endorse a vaccine against the coronavirus if it is not safe and effective, declared this Friday, September 4, its director general, Tedros Adhanom Ghebreyesus.

According to the WHO, there are 176 vaccine projects underway in the world, of which 34 are in the clinical trial phase, which means that they have started to be tested in humans. Among these, eight are in phase three, the most advanced.

Around the world, the pandemic has claimed so far the lives of more than 875,700 people and infected more than 26.6 million.


Newsletter

Related Articles

0:00
0:00
Close
Former Judge Charged After Drunk Driving Crash Kills Comedian in Brazil
Jeff Bezos hasn’t paid a dollar in taxes for decades. He makes billions and pays $0 in taxes, LEGALLY
China Increases Use of Exit Bans Amid Rising U.S. Tensions
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Procter & Gamble to Raise U.S. Prices to Offset One‑Billion‑Dollar Tariff Cost
House Republicans Move to Defund OECD Over Global Tax Dispute
Botswana Seeks Controlling Stake in De Beers as Anglo American Prepares Exit
Trump Administration Proposes Repeal of Obama‑Era Endangerment Finding, Dismantling Regulatory Basis for CO₂ Emissions Limits
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
×